Home » Stocks » CNST

Constellation Pharmaceuticals, Inc. (CNST)

Stock Price: $37.90 USD 1.40 (3.82%)
Updated Jan 20, 2021 2:05 PM EST - Market open
Market Cap 1.74B
Revenue (ttm) n/a
Net Income (ttm) -113.18M
Shares Out 47.53M
EPS (ttm) -2.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $37.90
Previous Close $36.50
Change ($) 1.40
Change (%) 3.82%
Day's Open 36.48
Day's Range 36.29 - 39.30
Day's Volume 401,561
52-Week Range 17.62 - 49.79

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced the appointment of Brendan Delaney to the newly created position of Chief...

GlobeNewsWire - 2 weeks ago

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that Jigar Raythatha, CEO, will present a company overview at the J.P. Mo...

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Dec. 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that two oral presentations and three posters relating to the Phase 2 MAN...

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Constellation   Pharmaceuticals ,  Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to dis...

Insider Monkey - 2 months ago

While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to ge...

Seeking Alpha - 2 months ago

Constellation Pharmaceuticals, Inc. (CNST) CEO Jigar Raythatha on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop n...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to di...

Seeking Alpha - 5 months ago

Constellation Pharmaceuticals, Inc. (CNST) CEO Jigar Raythatha on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to disco...

Zacks Investment Research - 5 months ago

Constellation Pharmaceuticals (CNST) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to disco...

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to disco...

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that three posters relating to the MANIFEST clinical trial of CPI-0610 ...

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to dis...

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...

Zacks Investment Research - 7 months ago

Constellation Pharmaceuticals, Inc. (CNST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research - 8 months ago

Constellation (CNST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Seeking Alpha - 8 months ago

Constellation Pharmaceuticals, Inc. (CNST) CEO Jigar Raythatha on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Constellation Pharmaceuticals, Inc. (CNST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 9 months ago

CAMBRIDGE, Mass., April 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to di...

Zacks Investment Research - 9 months ago

Constellation Pharmaceuticals (CNST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

Seeking Alpha - 10 months ago

Constellation Pharmaceuticals, Inc. (CNST) CEO Jigar Raythatha on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 11 months ago

Constellation Pharmaceuticals: An Exciting Mid-Stage Oncology Player For 2020

The Motley Fool - 1 year ago

Seven biotechs led the way.

Other stocks mentioned: ARQL, AXSM, DRRX, EVER, ISEE, KOD, PRVB, RCEL, SSI
The Motley Fool - 1 year ago

These stocks have soared 935% or more this year. Can they keep the momentum going?

Other stocks mentioned: AXSM, KOD
The Motley Fool - 1 year ago

Here's why these drugmaker stocks are the year's top performers.

Other stocks mentioned: AXSM, KOD
GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to disco...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to disco...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to disco...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...

Seeking Alpha - 1 year ago

Constellation Pharmaceuticals had $89.1 million in cash as of September 30, 2019, with enough funds to operate into the first half of 2021.

Investopedia - 1 year ago

These are the small cap stocks with the best value, fastest growth, and most momentum for November.

Other stocks mentioned: ACRE, APPS, AXSM, CNNE, CRC, CRZO, SIG, SWN
InvestorPlace - 1 year ago

Enjoying a blistering run within the last two months, CNST stock has quickly attracted eyeballs. But with such strong momentum, investors shouldn’t lose sight of the tough fundamental picture ...

The Motley Fool - 1 year ago

These stocks rose in a quiet market.

Other stocks mentioned: DVA, WIFI
The Motley Fool - 1 year ago

Great news from a phase 2 clinical study lit a fire beneath this drug stock.

Market Watch - 1 year ago

Shares of Constellation Pharmaceuticals Inc. jumped 95% after the biopharmaceutical company reported promising data from a mid-stage clinical trial for myelofibrosis.

Zacks Investment Research - 1 year ago

Does Constellation Pharmaceuticals, Inc. (CNST) have what it takes to be a top stock pick for momentum investors?

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Constellation Pharmaceuticals.

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to dis...

Zacks Investment Research - 1 year ago

Constellation Pharmaceuticals (CNST) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to disco...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to disc...

GlobeNewsWire - 1 year ago

Potential best-in-class EZH2 inhibitor focused on targeted patient segments was identified using Constellation’s epigenetics platform Potential best-in-class EZH2 inhibitor focused on targeted...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to dis...

About CNST

Constellation Pharmaceuticals, a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Its lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer in combination with androgen receptor signaling... [Read more...]

Industry
Biotechnology
IPO Date
Jul 19, 2018
CEO
Jigar Raythatha
Employees
106
Stock Exchange
NASDAQ
Ticker Symbol
CNST
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for CNST stock is "Buy." The 12-month stock price forecast is 45.67, which is an increase of 20.52% from the latest price.

Price Target
$45.67
(20.52% upside)
Analyst Consensus: Buy